Merck & Co. Inc. and Schering-Plough Corporation continue to pursue a patent infringement lawsuit against generic pharmaceutical manufacturers who filed abbreviated new drug applications for generic ezetimibe (Zetia).
An abbreviated new…
Merck & Co. Inc. and Schering-Plough Corporation continue to pursue litigation against generic companies over the infringement of the Zetia patent.
An abbreviated new drug application has been submitted to the…
Several purported antitrust class actions filed in the federal and state courts against Schering-Plough Corp. with regards to the drug, K-DUR, are still ongoing.
Schering-Plough had settled patent litigation with Upsher-Smith,…
A patent infringement action filed by Schering-Plough Corp. and an entity jointly owned with Merck & Co., Inc. against companies seeking approval of a generic version of ZETIA is ongoing.
The…
Schering-Plough Corp. continues pursuing patent infringement actions against companies seeking approval of generic versions of Clarinex Tablets, Clarinex Reditabs and Clarinex D12.
The Company filed these actions in September 2006. (Lloyds…
Schering-Plough Corp. and its licensor, Cancer Research Technologies, Limited, continues to pursue a patent infringement action against companies seeking approval of a generic version of certain strengths of TEMODAR capsules.
Schering-Plough…
Schering-Plough Corp.’s patent infringement action against companies seeking approval of a generic version of certain strengths of Temodar capsules is still pending.
The Company and its licensor, Cancer Research Technologies, Limited,…
Several purported antitrust class actions filed in the federal and state courts against Schering-Plough Corp. with regards to the drug, K-DUR, are still in discovery.
Schering-Plough had settled patent litigation with…
Schering-Plough Corp. and an entity jointly owned with Merck & Co., Inc. continue to pursue a patent infringement action against companies seeking approval of a generic version of ZETIA.
The action…
Schering-Plough Corp. is pursuing patent infringement actions against companies seeking approval of generic versions of Clarinex Tablets, Clarinex Reditabs and Clarinex D12.
The Company filed these actions in September 2006. (Lloyds…